Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dermatophagoides pteronyssinus and farinae allergen extracts for skin prick test: sensitivity and specificity
2025-522469-31-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- May 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of dermatophagoides pteronyssinus extract and dermatophagoides farinae in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), allergic asthma and 2 more (2 cohorts), sponsored by Inmunotek. Primary endpoint: Primary: Wheal area for Dermatophagoides extracts and controls. Planned start May 2026; status: authorised.
02
Drugs
dermatophagoides pteronyssinus extractdermatophagoides farinae
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthmahouse dust mite allergyDermatophagoides farinae allergy
Beyond the preview
Go deeper on 2025-522469-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522469-31-00.